Author

I. Jeremias

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:cancer & tumor microenvironment· 3 Organism:mouse· 3 Research Focus:cell type annotation· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Assay:ChIP-seq· 1 Research Focus:clustering· 1

Frequent Co-Authors

M. Carlet· 3 shared W.-H. Liu· 3 shared A. Deshpande· 2 shared T. Herold· 2 shared X. Lei· 2 shared A. Arner· 1 shared A. Bagchi· 1 shared A. Brown· 1 shared

Activity by Year

2019-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

M. Carlet

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

High Density Domain-Focused CRISPR Screens Reveal Novel Epigenetic Regulators of HOX/MEIS Activation in Acute Myeloid Leukemia

K. Barbosa, A. Deshpande, M. E. Perales, P. Xiang, R. Murad, A. Minkina, N. A. Robertson, F. Schischlik, X. Lei, Y. Sun, A. Brown, D. Amend, I. Jeremias, J. G. Doench, K. Humphries, , A. J. Deshpande

The paper identifies SGF29 as a novel chromatin regulator of MEIS1 and AML oncogenes, showing its role in leukemogenesis and potential as a drug target.

bioRxiv · Dec 12, 2022 · PreprintCancer Biology

A JAK/STAT-Mediated Inflammatory Signaling Cascade Drives Oncogenesis In AF10-Rearranged AML

B. Chen, A. Deshpande, K. O. Barbosa, M. Kleppe, X. Lei, N. Yeddula, A. Rosa Campos, R. Wechsler-Reya, A. Bagchi, S. Meshinchi, C. J. Eaves, I. Jeremias, T. Haferlach, D. Frank, Z. Ronai, , A. Deshpande

This study identifies JAK1 as a therapeutic target in AF10-rearranged AML by showing its role in JAK/STAT-mediated inflammatory signaling and oncogenesis.

bioRxiv · Aug 31, 2020Cancer Biology

In vivo inducible reverse genetics in patients' tumors to identify individual therapeutic targets

M. Carlet, K. Voelse, J. Vergalli, M. Becker, T. Herold, A. Arner, W.-H. Liu, V. Dill, B. Fehse, C. D. Baldus, L. Bastian, L. Lenk, D. M. Schewe, J. W. Bagnoli, P. J. Jost, , I. Jeremias

The paper develops an in vivo inducible RNAi system in patient-derived xenograft models to identify therapeutic targets in acute leukemias.

bioRxiv · May 2, 2020Cancer Biology

Inducible transgene expression in PDX models in vivo identifies KLF4 as therapeutic target for B-ALL

W.-H. Liu, P. Mrozek-Gorska, T. Herold, L. Schwarzkopf, D. Pich, K. Völse, A.-K. Wirth, M. C. Melo-Narvaez, M. Carlet, W. Hammerschmidt, I. Jeremias

The paper uses PDX models to show KLF4 re-expression reduces B-ALL leukemia load and sensitizes tumors to chemotherapy, suggesting Azacitidine could regulate KLF4 as a therapeutic option.

bioRxiv · Mar 6, 2020Cancer Biology

Functional plasticity and reversible growth behavior of patients acute myeloid leukemia stem cells growing in mice

S. Ebinger, C. Zeller, M. Carlet, D. Senft, W.-H. Liu, M. Rothenberg-Thurley, K. H. Metzeler, K. Spiekermann, B. Vick, I. Jeremias

This study shows AML stem cells can switch between low-cycling, treatment-resistant and actively proliferating states in mice, suggesting functional plasticity that could be targeted therapeutically.

bioRxiv · Jul 19, 2019 · PreprintCancer Biology